Pillser: Research Signals in a Supplement Market Full of Fluff

⬅️ Back to Articles

Source: Pillser Findings · HN discussion

The supplement aisle is marketing with a nutrition label. Pillser is trying the opposite: index every product and every paper, rank claims by effect type and size, then wire the two datasets together so you can see what the evidence actually says about what you are holding. The Findings feed is the readable front page—headline studies in plain language, with the population limits and “one trial so far” warnings in the same breath. The site is explicit: these are research signals worth knowing about, not prescriptions.

  1. The three-layer stack is the whole idea. Step one: parse the supplement market (ingredients, doses, normalized quantities). Step two: index supplementation research and score each claim. Step three: link products to papers. That is how you get from a Vitamin D search to a specific probiotic strain page to a product listing without trusting the brand’s ad copy.
  2. Findings reads like a good journal club, not a wellness blog. A typical card might say turmeric cut HbA1c by 0.31% in a meta-analysis—and immediately add: only in people with diabetes, only four small studies, low overall evidence strength. Or milk thistle: 2,069 people with fatty liver, ALT down 1.10 U/L, probably noise. Myth-busters matter as much as hype.
  3. You can browse by outcome, not by influencer. Health-outcome pages group what the literature claims about gut barrier function, eczema severity, sleep quality, and the rest—useful when you care about a question (“does anything help X?”) rather than a bottle name.
  4. Individual papers get an AI-assisted read—with receipts. Each research-paper page pulls study design, sample size, and effect direction into something scannable. The creator paused the project once because early LLMs hallucinated too often on this data; they restarted after internal evals improved. Worth watching: AI interpretation is only as good as the eval harness behind it.
  5. The mission is transparency, not more pills. The founder says the goal is not to increase supplement use but to help people decide—and often that decision is “you do not need this” or “get it from food.” This quarter’s focus is education on natural supplementation. That framing is rare in a category built on upsell.
  6. Restarting cost real friction. Shady brands sent cease-and-desist letters demanding product takedowns—usually big marketing budgets, weak ingredient-to-price ratios, per the creator. Legal drag plus grad school plus unreliable models was enough to shelve it. Bryan Johnson’s Blueprint wave brought inbound interest that helped justify picking it back up. Transparency projects still fight incumbents with lawyers.
  7. You might think a database fixes shopping. It does not fix you. Even perfect evidence summaries leave out your labs, medications, and contraindications. Pillser is a map of published signals, not a clinician. Single RCTs in narrow groups (Parkinson’s patients, postpartum wounds, preterm infants) dominate the feed—the caveats are honest, but readers still have to resist “one study → buy now.”

The takeaway: Bookmark pillser.com/findings as a filter before you read a supplement label or a Twitter thread. Use it to ask “what does the literature claim, for whom, and how weak is it?"—then talk to someone who can actually advise you on your body. If a finding is interesting, follow the paper link and treat the product pages as price-and-ingredient context, not a shopping list.

Related TMFNK Content

Crepi il lupo! 🐺